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Endoscopic palliation of malignant biliary obstruction through the placement of plastic or self-expandable metal stents (SEMS) is the standard treatment
for unresectable disease. Endobiliary radiofrequency ablation (RFA) is a therapeutic modality that has been recently used as a primary therapy to restore
biliary patency in unresectable biliary malignancies and to treat occluded uncovered biliary SEMS because of tumor ingrowth. Preliminary animal studies
have shown the tissue effects of RFA; however, the correlation of histopathologic ﬁndings in humans has not been reported. In this paper, we present two
patients with a surgically resectable malignant distal biliary obstruction that was secondary to pancreatic adenocarcinoma. After they underwent biliary
decompression, endobiliary RFA was performed. This was immediately followed by the placement of an uncovered biliary SEMS. Both patients subse-
quently underwent pancreaticoduodenectomy. A histopathologic review showed a circumferential zone of necrosis of 1.0–1.5 mm in depth. When
compared to published animal data, the zone of necrosis was demonstrably reduced. These discrepant ﬁndings are likely multifactorial (e.g., heat-sink
phenomenon, differences in study protocol, and comparison of dissimilar tissues). Based on our preliminary histopathologic ﬁndings, further studies
may be necessary to deﬁnitively determine the depth of penetration within the human bile duct during endobiliary RFA.
Copyright  2013, Society of Gastrointestinal Intervention. Published by Elsevier. All rights reserved.
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Endoscopic palliation of malignant biliary obstruction is the
primary treatment for patients with surgically unresectable dis-
ease. The placement of plastic or self-expandable metal stents
(SEMS) provides decompression of malignant biliary obstruction
from extrahepatic cholangiocarcinoma or pancreatic adenocarci-
noma.1–4 Uncovered SEMS lose their patency over a period of 3–6
months, primarily because of tumor ingrowth or overgrowth.5
Photodynamic therapy (PDT) for hilar cholangiocarcinomadwith
or without biliary SEMSddemonstrably reduces cholestasis, im-
proves quality of life, and increases survival rates.6–8 However, PDT
is limited by availability, photosensitivity, procedural cost, and the
need for repeated treatment sessions.
Endobiliary radiofrequency ablation (RFA) has recently
become a therapeutic option for treating malignant biliary
obstruction. Endobiliary RFA delivers a temperature-dependent
and time-dependent energy deposition into bile duct tumors,
and thereby induces thermal injury and subsequent localized
necrosis.9 Early reports suggest RFA can be used as the primary
therapy for unresectable biliary malignancies and used to restore
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biliary RFA, followed by SEMS placement in patients with ma-
lignant biliary obstruction (16 cases of pancreatic adenocar
cinoma and 6 cases of cholangiocarcinoma), resulted in 90% stent
patency at 30 days and continued stent patency at 90 days.
Radiofrequency ablation of malignant biliary obstruction prior to
SEMS insertion may delay the occlusion of uncovered SEMS by
tumor ingrowth.
Reports have been published of in vivo and ex vivo porcine
models to assess endobiliary RFA.12,13 However, the correlationwith
human histopathologic ﬁndings has not been reported. In this
paper, we describe the ﬁrst gross and microscopic ﬁndings in the
human bile duct after radiofrequency ablation.Case report
Two patients underwent endobiliary RFA, followed by pan-
creaticoduodenectomy at the Imperial College London (London,
United Kingdom), for pancreatic adenocarcinoma that had caused
malignant biliary obstruction. Patient 1 was a 76-year-old manwith
compensated hepatitis B cirrhosis and systemic arterial hyperten-
sion who presented with recent weight loss and jaundice (hisst Street SW, Rochester, MN 55905, USA.
on. Published by Elsevier. All rights reserved.
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a 74-year-old man who also presented with recent weight loss and
jaundice (his bilirubin level was 26.9 mg/dL) over the previous 8
weeks. In both patients, computed tomography (CT) revealed an
obstructing pancreatic head mass.
Endoscopic retrograde cholangiopancreatography (ERCP) using a
standard video duodenoscope (Olympus TJF-160VR; Olympus
America, CenterValley, PA,USA) conﬁrmedadistal commonbile duct
(CBD) stricture in both patients. After placing a 10 Fr 7-cm biliary
stent for initial decompression, an endoscopic ultrasound (EUS) and
repeat ERCPwereperformedat 2weeks inPatient 1 andat 5weeks in
Patient 2. The EUS demonstrated resectable lesions. Fine-needle
aspiration conﬁrmed adenocarcinoma in both patients. Repeat
ERCP with RFA (Habib EndoHPB catheter; EMcision UK, London,
United Kingdom)was performed to provide optimal biliary drainage
and potentially mitigate tumor ingrowth and overgrowth in the
event that surgical intervention was delayed. Energy was delivered
by a RFA generator (1500 RF generator; RITA Medical Systems, Inc.,
Fremont, CA, USA), which delivered electrical energy at 400 kHz at
10 W for 120 seconds. Sequential applications were applied
throughout the length of the stricture with a 1-minute rest period
between applications. Immediately after RFA, an uncovered biliary
SEMS (Wallﬂex RX; Boston Scientiﬁc, Natick, MA, USA)d10 mm in
diameter and 80 mm in lengthdwas placed. Both patients under-
went successful pancreaticoduodenectomy 20 days later (Patient 1)
and 32 days later (Patient 2).
Gross examination of the resected specimens revealed a patent
CBD with a zone of necrosis at the RFA treatment area (Fig. 1). A
histologic review of Patient 1 demonstrated a circumferential area of
necrosis that was limited to the mucosa (Fig. 2A). It was 1 mm thick
(Fig. 2B). A dense mixed inﬂammatory inﬁltrate surrounded the
zone of necrosis.
The resected specimen from Patient 2 revealed focal tumor
inﬁltration into the CBD wall and within the partially necrotic and
inﬂammatory zone surrounding the dilated and denuded CBD. This
necrotic inﬂammatory zone surrounding the CBD measured up to
1.5 mm in thickness.Fig. 1. Gross pathologic specimen after Whipple resection demonstrates a patent
common bile duct after endobiliary RFA and biliary SEMS placement. RFA, radio-
frequency ablation; SEMS, self-expandable metal stents.Discussion
The initial results of endobiliary RFA show its safety and efﬁcacy
as a treatment for malignant biliary obstruction.11 This technique
evolved from similar percutaneous and intraoperative techniques
used for treating primary and secondary hepatic cancers.14,15 The
commercially available Habib EndoHPB catheter (EMcision UK) is an
8 Fr (2.6 mm) 1.8 m long bipolar radiofrequency (RF) catheter that
passes over a 0.035 inch guidewire and across malignant strictures
during ERCP or percutaneous transhepatic cholangiography. The
distal tip of the catheter has two stainless steel ring electrodes that
deliver controlled RF energy through contacted tissues.13 The
delivered energy results in rapid ionic motion, thereby generating
heat around the probe and within surrounding tissues, and even-
tually culminating in coagulative necrosis.16
Experimental studies using porcine models have evaluated the
gross and histopathologic changes immediately following endo-
biliary RFA. Zacharoulis et al13 and Itoi et al12 demonstrated a
positive correlation between the amount of RF energy delivered
and the extent of thermal injury. However, Zacharoulis et al13 uti-
lized an in vivo healthy porcine model. The researchers noted that
6–7 W delivered over 50–60 seconds induced full thickness coag-
ulation of the bile duct wall without injuring surrounding struc-
tures. Itoi et al12 positioned the RFA catheter directly into freshly
resected porcine liver parenchyma, and attempted to mimic ma-
lignant biliary obstruction. Maximal energy of 20 W delivered over
a 120-second application time yielded 11.3 1.2 mm of penetration
and 29.0  1.0 mm of spread, compared to 4.3  0.6 mm of pene-
tration and 11.0  1.0 mm of spread by using the minimal settings
(i.e., 5 W for 60 seconds). The zone of necrosis was microscopically
equivalent to the grossly measured area of ablation. Based on
experimental and initial clinical data, the settings of 7–10 W
delivered over 120 seconds are believed to be adequate baseline
RFA settings11; however, characteristics such as tumor size, bile
duct wall thickness, and the anatomic relationship to surrounding
structures need to be considered.
Our patients were treated with endobiliary RFA set at 10 W for
120 seconds. Both patients subsequently underwent pan-
creaticoduodenectomy, which included resection of the RFA-
treated area. The histological circumferential zone of necrosis was
1 mm (Patient 1) and 1.5 mm (Patient 2). These results are notably
discrepant in comparison to the 10.3  0.6 mm of penetration
noted when identical settings were used in the ex vivo porcine
model.12 The conﬂicting ﬁndings can likely be explained by a
combination of the heat-sink phenomenon, differences in study
protocols, and the comparison of dissimilar tissues. Blood ﬂow
within tissue surrounding the human CBDdincluding the portal
vein and hepatic arterydprovides a cooling or heat-sink effect that
could account for the minimal necrosis observed in our patients.
Both patients underwent SEMS placement immediately after un-
dergoing RFA. The histologic evaluation was moreover performed
at least 20 days (Patient 1) and 32 days (Patient 2) after the index
RFA procedure. Radial expansion of the SEMS may have com-
pressed necrotic tissue, causing a modest zone of necrosis in
comparison to the zone of necrosis in the ex vivo ﬁndings. The
ex vivo liver histologic evaluation occurred immediately after RFA,
whereas in our patients it was delayed, thereby allowing for tissue
healing within the bile duct and/or sloughing of necrotic intra-
ductal debris. Tissue differences may account for the discrepant
ﬁndings. The RFA catheter was placed directly into the porcine liver
parenchyma during the ex vivo study and into an otherwise normal
porcine CBD in the in vivo study. These tissues are not identical to
that of our patients. The response to RFA is likely to be different
when comparing porcine versus human tissue and healthy versus
Fig. 2. Whipple resection. (A) Microscopic view of the common bile duct after Whipple resection. (B) The 1-mm area of circumferential necrosis is surrounded by an additional 1-
mm area of acute inﬂammation (20 magniﬁcation).
Gastrointestinal Intervention 2013 2(2), 124–126126cancerous tissue. It is impossible to discern whether applying RFA
produced ablation beyond the tumor margin in our patients.
This case report is the ﬁrst description of the human bile duct
after endobiliary RFA. Further human studies are needed to deter-
mine optimal RFA settings in patients with malignant biliary
obstruction.
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